부산대학교 도서관

Primary tracheal cancer is a rare disease entity which represents 0.1-0.4% of all newly diagnosed cancers every year. Adenoid cystic carcinoma is the second most common histological type of tracheal cancer. The primary treatment modality is surgical excision. Post-operative radiotherapy also shows benefit in disease-free survival and overall survival. However, there were no randomized trials for post-operative chemoradiotherapy in patients with close margin due to its low incidence. Here, we present a 52-year-old female adenoid cystic carcinoma patient with a history of right breast mucinous carcinoma. After primary surgical resection, the patient received adjuvant concurrent chemoradiotherapy due to positive margin. Radiotherapy 60 Gy together with weekly cisplatin 30 mg/m^2 were delivered within six weeks. The patient was followed at our outpatient clinic for 1 more year after the initial surgery. No severe complications were found except for a persistant weak voice due to left vocal cord palsy. The patient's phonation improved after intracordal hyaluronic acid injection. We concluded that postoperative adjuvant concurrent chemoradiotherapy (CCRT) may be a good treatment modality for tracheal adenoid cystic carcinoma.